The influence of heart failure on clinical and economic outcomes among older adults ≥75 years of age with acute myocardial infarction.


Journal

American heart journal
ISSN: 1097-6744
Titre abrégé: Am Heart J
Pays: United States
ID NLM: 0370465

Informations de publication

Date de publication:
04 2022
Historique:
received: 26 05 2021
revised: 08 11 2021
accepted: 20 11 2021
pubmed: 20 12 2021
medline: 8 4 2022
entrez: 19 12 2021
Statut: ppublish

Résumé

We aimed to evaluate the influence of heart failure (HF) on clinical and economic outcomes among older adults ≥75 years of age during their acute myocardial infarction (AMI) admission in large population-based study from the United States. We also evaluated the clinical characteristics associated with the presence of HF and the predictors of mortality, healthcare utilization, and cost among older adults with AMI. From January 1, 2000, to December 31, 2016, AMI admission was identified using the primary diagnosis and concomitant HF was identified using any non-primary diagnoses in the Premier Healthcare Database. Of the 468,654 patients examined, 42,946 (9%) had concomitant HF during their AMI admission. These patients were older, more often female, and were more likely to be White. Patients with concomitant HF were more likely to be frail than non-HF patients (59% vs 15%, P < .001). The mean (SD) Elixhauser comorbidity index was 2.6 (2.5) vs 0.4 (1.1), P < .001 in the AMI with HF vs AMI only group. The use of percutaneous coronary intervention in those with AMI and HF was lower than those with AMI only (15% vs 31%, P < .001). The overall mortality rate for those with HF was 12%, the median [IQR] hospital length of stay was 5 [3,9] days, and only 25% of patients were discharged home. A higher proportion of patients were discharged to rehabilitation or hospice if they had AMI and HF (Rehabilitation: 33% vs 20%, P < .001; Hospice: 5% vs 3%, P < .001). The mean unadjusted cost of an AMI hospitalization in patients with concomitant HF was lower ($12,411 ± $14,860) than in those without HF ($15,828 ± $19,330). After adjusting for age, gender, race, hypertension, frailty, revascularization strategy, and death, the average cost of hospitalization attributed to concomitant HF was +$1,075 (95% CI +876 to $1,274) when compared to AMI patients without HF. In patients ≥75 years of age, AMI with concomitant HF carries higher risk of death, but at ages ≥85 years, the risk difference diminishes due to other competing risks. HF was also associated with longer hospital length of stay and higher likelihood of referral to hospice and rehabilitation facilities when compared to older patients without HF. Care for these older adults is associated with increased hospitalization costs. Measures to identify HF in older adults during their AMI admission are necessary to optimize health outcomes, care delivery, and costs.

Sections du résumé

BACKGROUND
We aimed to evaluate the influence of heart failure (HF) on clinical and economic outcomes among older adults ≥75 years of age during their acute myocardial infarction (AMI) admission in large population-based study from the United States. We also evaluated the clinical characteristics associated with the presence of HF and the predictors of mortality, healthcare utilization, and cost among older adults with AMI.
METHODS
From January 1, 2000, to December 31, 2016, AMI admission was identified using the primary diagnosis and concomitant HF was identified using any non-primary diagnoses in the Premier Healthcare Database.
RESULTS
Of the 468,654 patients examined, 42,946 (9%) had concomitant HF during their AMI admission. These patients were older, more often female, and were more likely to be White. Patients with concomitant HF were more likely to be frail than non-HF patients (59% vs 15%, P < .001). The mean (SD) Elixhauser comorbidity index was 2.6 (2.5) vs 0.4 (1.1), P < .001 in the AMI with HF vs AMI only group. The use of percutaneous coronary intervention in those with AMI and HF was lower than those with AMI only (15% vs 31%, P < .001). The overall mortality rate for those with HF was 12%, the median [IQR] hospital length of stay was 5 [3,9] days, and only 25% of patients were discharged home. A higher proportion of patients were discharged to rehabilitation or hospice if they had AMI and HF (Rehabilitation: 33% vs 20%, P < .001; Hospice: 5% vs 3%, P < .001). The mean unadjusted cost of an AMI hospitalization in patients with concomitant HF was lower ($12,411 ± $14,860) than in those without HF ($15,828 ± $19,330). After adjusting for age, gender, race, hypertension, frailty, revascularization strategy, and death, the average cost of hospitalization attributed to concomitant HF was +$1,075 (95% CI +876 to $1,274) when compared to AMI patients without HF.
CONCLUSION
In patients ≥75 years of age, AMI with concomitant HF carries higher risk of death, but at ages ≥85 years, the risk difference diminishes due to other competing risks. HF was also associated with longer hospital length of stay and higher likelihood of referral to hospice and rehabilitation facilities when compared to older patients without HF. Care for these older adults is associated with increased hospitalization costs. Measures to identify HF in older adults during their AMI admission are necessary to optimize health outcomes, care delivery, and costs.

Identifiants

pubmed: 34922928
pii: S0002-8703(21)00474-9
doi: 10.1016/j.ahj.2021.11.021
pmc: PMC8917998
mid: NIHMS1764985
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

65-73

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL153771
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG021334
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no relevant interests.

Références

Am Heart J. 1999 Dec;138(6 Pt 1):1133-9
pubmed: 10577445
J Am Med Inform Assoc. 2017 Jul 01;24(4):845-850
pubmed: 28339644
Circulation. 2020 Jan 14;141(2):e6-e32
pubmed: 31813278
Am J Med. 2021 May;134(5):662-671.e1
pubmed: 33242482
J Am Heart Assoc. 2016 Jan 07;5(1):
pubmed: 26744379
Circ Cardiovasc Interv. 2019 May;12(5):e007812
pubmed: 31010297
J Am Heart Assoc. 2019 Sep 3;8(17):e013686
pubmed: 31475601
Cardiovasc Revasc Med. 2021 Jul;28:95-97
pubmed: 32798116
Am J Med. 2002 Sep;113(4):324-30
pubmed: 12361819
Circ Heart Fail. 2018 Dec;11(12):e004873
pubmed: 30562099
Risk Manag Healthc Policy. 2017 May 10;10:63-70
pubmed: 28546776
Am Heart J. 2020 May;223:1-2
pubmed: 32112871
Circulation. 2002 Jun 4;105(22):2605-10
pubmed: 12045165
Circ Heart Fail. 2012 Nov;5(6):693-702
pubmed: 23051950

Auteurs

Swetha Pasala (S)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Lauren B Cooper (LB)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Mitchell A Psotka (MA)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Shashank S Sinha (SS)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Christopher R deFilippi (CR)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Henry Tran (H)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Behnam Tehrani (B)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Matthew Sherwood (M)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Kelly Epps (K)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Wayne Batchelor (W)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA.

Abdulla A Damluji (AA)

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: Abdulla.Damluji@jhu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH